Меню
Набор скоро начнётся NCT07692997

Sancai Fengsui Decoction for RTOM: A Multicenter RCT

Фаза II С лечением Radiation-Induced Oral Mucositis (RTOM) Head and Neck Cancer Oral Mucositis of RTOG Grade Greater Than 1

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Sancai Fengsui Decoction, Placebo Group.
Кому может быть актуально
Состояния в реестре: Radiation-Induced Oral Mucositis (RTOM), Head and Neck Cancer, Oral Mucositis of RTOG Grade Greater Than 1. Базовые параметры: 18 лет — 65 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Список центров уточняется — проверьте первичный протокол.
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

A Multicenter Randomized Controlled Trial to Evaluate the Rehabilitative Efficacy of Sancai Fengsui Decoction on Radiation-Induced Oral Mucositis.

Обзор

How to promote the prognosis and outcome of RTOM, restore oral function, and improve quality of life are key issues for improving the long-term outcomes of head and neck malignant tumor radiotherapy, and are also integral parts of the patient-centered Traditional Chinese Medicine "prevention-treatment-rehabilitation" system for RTOM. This project aims to thoroughly evaluate the efficacy and safety of Chinese herbal compounds in the rehabilitation phase of RTOM, targeting the long-term rehabilitation outcomes of RTOM, and to conduct a phase II clinical trial. In this project, Sancai Fengsui Decoction will be used as an oral medication to improve the rehabilitation status of RTOM, and will be compared with a placebo group. The efficacy of the oral medication will be evaluated by comparing outcome measures including the 2-week pain relief rate in the oral cavity/oropharynx, the RTOG grade remission rate for RTOM, and the relief rate of xerostomia. As an important extension of TCM prevention and treatment for RTOM, this project can provide a high-level evidence-based TCM protocol for the long-term rehabilitation of RTOM.

Вмешательства

  • Препарат Sancai Fengsui Decoction
    To investigate the efficacy of Sancai Fengsui Decoction in the treatment of RTOM，orally administered Sancai Fengsui Decoction, 30 mL per dose, three times daily, with a treatment course of two weeks.
  • Препарат Placebo Group
    The control group received a placebo that matched the color, odor, and taste of the Sancai Fengsui Decoction but contained no active ingredients of the decoction. The usage and dosage were the same as those in the Sancai Fengsui Decoction group.

Первичные конечные точки

  • Pain relief rate in the oral cavity/oropharynx [Срок оценки: Proportion of patients with significant improvement in pain level from baseline at 2 weeks after enrollment, assessed using the Numeric Rating Scale (NRS).]
Вторичные конечные точки (6)
  • RTOG score remission rate of RTOM [Срок оценки: Evaluated at 2 weeks post-radiotherapy]
  • 3-month xerostomia relief rate [Срок оценки: From enrollment (Day 0) through Month 3, spanning the entire radiotherapy treatment period.]
  • Analgesic medication use [Срок оценки: Baseline (screening/enrollment), week 1 and week 2 of the treatment period, weeks 1 through 6 of the follow-up period (weekly), and week 10 of the follow-up period.]
  • Usage of nutrient solutions/nutritional powders [Срок оценки: Baseline (screening/enrollment), week 1 and week 2 of the treatment period, weeks 1 through 6 of the follow-up period (weekly), and week 10 of the follow-up period.]
  • European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 [Срок оценки: Baseline (screening), treatment week 2, and follow-up weeks 2, 6, and 10]
  • European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck 35 [Срок оценки: Baseline (screening), treatment week 2, and follow-up weeks 2, 6, and 10]

Критерии участия

Критерии включения

  • Meets the diagnostic criteria for RTOM, with severity classified according to the RTOG grading system;
  • Voluntarily participates in this study and signs the informed consent form;
  • Age between 18 and 65 years;
  • Histopathologically diagnosed with non-metastatic head and neck malignancy;
  • Has received radiotherapy or concurrent chemoradiotherapy;
  • ECOG performance status score: 0-2;
  • Adequate major organ function.
  • Exclusion Criteria:
  • Patients with severe heart, lung, liver, kidney, digestive system, hematopoietic system, or nervous system diseases; acute infectious diseases; autoimmune diseases; HIV; diabetes mellitus with poor blood glucose control; or any other serious condition that, in the investigator's judgment, may increase the risk of the study, interfere with study execution or result analysis, or make the subject unsuitable for enrollment for other reasons;
  • Pregnant or breastfeeding women;
  • Allergic constitution;
  • Patients with severe psychiatric disorders, or a history of alcohol or drug abuse;
  • Participation in another clinical trial within the past 3 months;
  • Subjects deemed unsuitable for participation in this clinical study by the investigator.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Четверное слепое
Основная цель
Лечение

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Идентификаторы

NCT: NCT07692997 · NFEC-2026-211

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗